What is it about?
Developing a metabolomic prediction score for the presence of prostate cancer
Featured Image
Why is it important?
The PSA values between 4-10 ng/ml are called the "grey-zone". There is suspicion for prostate cancer, but an important percentage of the prostate biopsies will be negative. The metabolomic prediction score helps to select the patients who have a high probability of being diagnosed with prostate cancer and perform the biopsy only for them. In patients with low probability of prostate cancer, the biopsy can be deferred.
Perspectives
The metabolomic analysis is a step towards individualized medicine by selecting the patients with aggressive disease, in whom immediate treatment is curative, from those with indolent prostate cancer, for whom the confirmatory biopsy can be deferred in order to lower the rate of overtreatment.
Iulia Andras
Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
Read the Original
This page is a summary of: Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml, Future Oncology, August 2017, Future Medicine,
DOI: 10.2217/fon-2017-0078.
You can read the full text:
Contributors
The following have contributed to this page
